Nitazoxanide against COVID-19 in three explorative scenarios

  • José Meneses Calderón “Mónica Pretelini Sáenz” Maternal-Perinatal Hospital (HMPMPS), Toluca, Mexico
  • Ma. del Rocío Figueroa Flores Private Practice, Toluca, Mexico
  • Leopoldo Paniagua Coria “Mónica Pretelini Sáenz” Maternal-Perinatal Hospital (HMPMPS), Toluca, Mexico
  • Jesús Carlos Briones Garduño “Mónica Pretelini Sáenz” Maternal-Perinatal Hospital (HMPMPS), Toluca, Mexico
  • Jazmín Meneses Figueroa Faculty of Medicine, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico
  • María José Vargas Contretas Faculty of Medicine, Autonomous University of the State of Mexico (UAEMéx), Toluca, Mexico
  • Lilia de la Cruz Ávila “Mónica Pretelini Sáenz” Maternal-Perinatal Hospital (HMPMPS), Toluca, Mexico
  • Salvador Díaz Meza “Dr. Nicolás San Juan” General Hospital, Toluca, Mexico
  • Reynaldo Ramírez Chacón Instituto de Seguridad Social al Servicio de los Trabajadores del Estado (ISSSTE), Tabasco, Mexico
  • Srivatsan Padmanabhan St. Joseph Medical Center, Tacoma, WA, United States
  • Hugo Mendieta Zerón “Mónica Pretelini Sáenz” Maternal-Perinatal Hospital (HMPMPS), Toluca, Mexico
Keywords: Ambulatory treatment, internal medicine, nitazoxanide, pregnancy, SARS-CoV-2

Abstract

Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting.

Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City.

Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clinical improvement.

Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.

Published
2020-09-30
How to Cite
1.
Meneses Calderón J, Figueroa Flores M del R, Paniagua Coria L, Briones Garduño JC, Meneses Figueroa J, Vargas Contretas MJ, de la Cruz Ávila L, Díaz Meza S, Ramírez Chacón R, Padmanabhan S, Mendieta Zerón H (2020) Nitazoxanide against COVID-19 in three explorative scenarios. J Infect Dev Ctries 14:982-986. doi: 10.3855/jidc.13274
Section
Coronavirus Pandemic